Lifestyle and Pharmacological Interventions in Hypertrophic Cardiomyopathy
NCT05366101 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 168
Last updated 2022-05-09
Summary
The overall aim of this project is to establish potential benefits of a novel lifestyle (physical activity and dietary nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor) interventions in patients with hypertrophic cardiomyopathy (HCM). HCM is the most common genetic cardiovascular disease with a broad spectrum of disease severity. Angiotensin receptor neprilysin inhibitor reduces death, hospitalisation, and may improve cardiac function and exercise tolerance in heart failure. Exercise training is associated with a significant increase in exercise tolerance, but appear to have limited effect on measures of cardiac morphology or function in patients with HCM. Dietary supplementation with inorganic nitrate (i.e. concentrated nitrate-rich beetroot juice) improves exercise capacity, vasodilatation and cardiac output reserves while reduces arterial wave reflections, which are linked to left ventricular diastolic dysfunction and remodelling. Using a five-centre, open label, three-arm, pilot design, the present study will evaluate the effect of lifestyle (physical activity and dietary supplementation with inorganic nitrate) and pharmacological (angiotensin receptor neprilysin inhibitor sacubitril / valsartan) interventions in patients with HCM. The Aim is to examine whether these interventions improve functional capacity, clinical phenotypic characteristics, and quality of life in patients with HCM.
Conditions
Interventions
- DRUG
-
Sacubitril/Valsartan
Sacubitril / Valsartan as a pharmacological agent shall be studied to verify its effects on cardiac morphology and physiology of hypertrophic cardiomyopathy patients.
- BEHAVIORAL
-
Lifestyle
A 4-month lifestyle intervention will consist of two integrated components i.e. physical activity and dietary supplementation with inorganic nitrate. The physical activity component aims to increase daily physical activity level by at least 2000 steps/day from baseline (e.g. walking for approximately 30 minutes), at least 5-7 days per week. The second component of the lifestyle intervention is a dietary supplementation with inorganic nitrate. A single dose of inorganic nitrate given in the form of concentrated nitrate-rich beetroot juice (NO3-, BEET IT Sport, James White Drinks Ltd., Ipswich, UK) containing 6 mmol of NO3- in 70 ml bottle.
Sponsors & Collaborators
-
University Hospital Regensburg
collaborator OTHER -
Assistance Publique - Hôpitaux de Paris
collaborator OTHER -
Azienda Ospedaliero-Universitaria Careggi
collaborator OTHER -
Institute of Cardiovascular Diseases, Vojvodina
collaborator OTHER -
Newcastle-upon-Tyne Hospitals NHS Trust
lead OTHER
Principal Investigators
-
Djordje Jakovljevic, PhD · Faculty of Medical Sciences, Newcastle University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-01
- Primary Completion
- 2022-02-28
- Completion
- 2022-03-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Early Detection of Diastolic Dysfunction and the Role of Lifestyle Measures in Its Treatment
NCT00998114 ·Status: COMPLETED ·Phase: NA
-
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
NCT05168462 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate
NCT02612298 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris
NCT00424801 ·Status: TERMINATED ·Phase: NA
-
Analysis of Atropine and Propranolol Induced Changes
NCT00251602 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Study Assessing the Potential of Piboserod for the Treatment of Heart Failure
NCT00421746 ·Status: COMPLETED ·Phase: PHASE2
-
Beta-blockers in i-PAH
NCT01246037 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function
NCT01961453 ·Status: WITHDRAWN ·Phase: PHASE2
-
Tight Hemodynamic Control in Patients Who Are Chronically on Metoprolol
NCT01404767 ·Status: TERMINATED ·Phase: PHASE4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
NCT05593055 ·Status: RECRUITING ·Phase: PHASE4
-
24 Hour Ambulatory Cardiac Oxygen Consumption
NCT05170061 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Beta Blockade on Left Ventricular Remodeling and Function in Moderate to Severe Asymptomatic Aortic Regurgitation
NCT01157572 ·Status: COMPLETED ·Phase: PHASE4
-
Targeting Sympathetic Overactivity in Heart Failure Patients With Statins
NCT01097785 ·Status: COMPLETED ·Phase: NA
-
Cardiac Metabolic Modulator Treatment for Improvement of Diastolic Function in Patients With Coronary Heart Disease
NCT03887013 ·Status: UNKNOWN ·Phase: PHASE4
-
Exercise and Pharmacotherapy for Anxiety in Cardiac Patients
NCT02516332 ·Status: COMPLETED ·Phase: NA
-
The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris
NCT06415227 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
NCT01798992 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure
NCT02282618 ·Status: UNKNOWN
-
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension
NCT01970059 ·Status: UNKNOWN ·Phase: PHASE3
-
Treatment of Refractory Angina Pectoris by Shock Wave Therapy
NCT00776568 ·Status: UNKNOWN ·Phase: PHASE3
-
Cardiovascular Medication Use Before First Myocardial Infarction
NCT01692795 ·Status: COMPLETED
-
Study of the Effect of Moxonidine and Diet on Sympathetic Functions in Young Adults With Obesity
NCT01180231 ·Status: UNKNOWN ·Phase: PHASE4
-
Heart Rate Control Before Cardiac Computed Tomography in Adults for the Evaluation of Coronary Artery Disease
NCT07268170 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Safety Study of Pyridostigmine in Heart Failure
NCT01415921 ·Status: COMPLETED ·Phase: PHASE2
-
pErsonalised Nocebo Assessment of Beta-blockEr Symptoms in Heart Failure
NCT07029906 ·Status: RECRUITING ·Phase: NA